Candel Therapeutics: Compelling Clinical Phase 3 Data and a $22 Price Target by Stifel!

Candel Therapeutics (CADL) recently published crucial Phase 3 data (PrTK03) for its lead candidate Aglatimagene Besadenovec, demonstrating a significant improvement in disease-free survival for patients with localized prostate cancer. Additionally, the Phase 3 AURORA study has commenced. Experts at Stifel are now optimistic, which is why the stock was rated "Buy" with a price target of $22. The Massachusetts-based biotech company Candel Therapeutics (CADL) is increasingly attracting the interest of institutional investors as of Summer 2026. The...